Seer Appoints Anthony Bazarko as Chief Commercial Officer

Seer ( (SEER) ) has issued an update.

On May 4, 2026, Seer, Inc., a Nasdaq-listed life sciences tools company specializing in deep, unbiased proteomics, announced the appointment of veteran commercial executive Anthony Bazarko as Chief Commercial Officer. Seer develops and markets the Proteograph Product Suite, an integrated platform of nanoparticles, automation, consumables and analytical software used for large-scale proteomic research rather than diagnostic procedures.

Bazarko, who has previously held senior roles at Biologos, Specific Diagnostics, Danaher’s Leica Biosystems and Roche Diagnostics, was appointed to lead Seer’s sales, marketing and customer experience organizations. The move is intended to strengthen commercial execution, accelerate global adoption of the Proteograph platform and support Seer’s push to solidify its position in next-generation proteomics amid rising demand for high-throughput, AI-ready proteomic data from research customers worldwide.

The most recent analyst rating on (SEER) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Seer stock, see the SEER Stock Forecast page.

Spark’s Take on SEER Stock

According to Spark, TipRanks’ AI Analyst, SEER is a Neutral.

The score is held back primarily by persistent losses and cash burn (despite improving margins) and bearish technicals with the stock trading below major moving averages. Conservative 2026 guidance and funding uncertainty add pressure, partially offset by low leverage, disciplined expense reductions, and management’s expectation of continued free-cash-flow improvement supported by its stated cash position.

To see Spark’s full report on SEER stock, click here.

More about Seer

Seer, Inc., listed on Nasdaq as SEER, operates in the life sciences tools industry with a focus on deep, unbiased proteomics. The company’s Proteograph Product Suite combines engineered nanoparticles, automation instruments, consumables and analytical software to overcome throughput and complexity limits in traditional proteomic methods, serving research customers rather than diagnostic applications.

Seer positions itself as a provider of next-generation proteomics solutions designed to deliver large-scale, precise protein insights to scientists. By enabling higher depth, speed and reproducibility in proteomic analysis, the company aims to support AI-driven biology and expand access to advanced proteomic workflows across global research markets.

Average Trading Volume: 397,863

Technical Sentiment Signal: Sell

Current Market Cap: $114.5M

See more insights into SEER stock on TipRanks’ Stock Analysis page.